Table 1 Complement analysis before and... | American Society of Hematology

Table 1

Complement analysis before and after eculizumab infusion

	Day*	C3 level (mg/L)	C4 level (mg/L)	sC5B9 level (mg/L)
Patient 1
Before eculizumab infusion	0	1080	266	856
First follow-up assessment	2	1030	283	1223
Second follow-up assessment	14	1050	248	1406
Patient 2
Before eculizumab infusion	0	—	—	—
First follow-up assessment	7	1270	257	1797
Patient 3
Before eculizumab infusion	0	1070	220	1527
First follow-up assessment	4	313	104	296
Second follow-up assessment	6	359	129	224
Third follow-up assessment	9	928	526	355
Fourth follow-up assessment	13	1210	290	509

	Day*	C3 level (mg/L)	C4 level (mg/L)	sC5B9 level (mg/L)
Patient 1
Before eculizumab infusion	0	1080	266	856
First follow-up assessment	2	1030	283	1223
Second follow-up assessment	14	1050	248	1406
Patient 2
Before eculizumab infusion	0	—	—	—
First follow-up assessment	7	1270	257	1797
Patient 3
Before eculizumab infusion	0	1070	220	1527
First follow-up assessment	4	313	104	296
Second follow-up assessment	6	359	129	224
Third follow-up assessment	9	928	526	355
Fourth follow-up assessment	13	1210	290	509

C3, C3 complement component (normal range, 660-1250 mg/L); C4, C4 complement component (normal range, 93-380 mg/L); sC5B9, soluble terminal complement complex (normal range, <450 ng/mL).

Day after first eculizumab injection.

View Large

This Feature Is Available To Subscribers Only